In Response to 'Options for the Treatment of Gemcitabine-Resistant Advanced Pancreatic Cancer: Are We There Yet?'

  • Ioannis Gounaris Oncology Centre, Cambridge University Hospitals NHS Trust. Cambridge, United Kingdom
  • Kamarul Zaki Oncology Centre, Cambridge University Hospitals NHS Trust. Cambridge, United Kingdom
  • Pippa Corrie Oncology Centre, Cambridge University Hospitals NHS Trust. Cambridge, United Kingdom
DOI: https://doi.org/10.6092/1590-8577/3835
Keywords: Drug Therapy, gemcitabine, Neoplasm Metastasis, Pancreatic Neoplasms

Abstract

No abstract available.

Image: Addenbrooke’s Hospital. Cambridge, United Kingdom.

Downloads

Download data is not yet available.

References

Gounaris I, Zaki K, Corrie P. Options for the treatment of gemcitabine-resistant advanced pancreatic cancer. JOP. J Pancreas (Online) 2010; 11:113-23. [PMID 20208317] (FULLTEXT: http://www.joplink.net/prev/201003/09.html)

Addenbrooke’s Hospital. Cambridge, United Kingdom
Published
2010-05-05
How to Cite
GounarisI., ZakiK., & CorrieP. (2010). In Response to ’Options for the Treatment of Gemcitabine-Resistant Advanced Pancreatic Cancer: Are We There Yet?’. JOP. Journal of the Pancreas, 11(3), 290. https://doi.org/10.6092/1590-8577/3835
Issue
Vol 11 No 3 (2010): May - p. 199-298
Section
REPLY

Copyright (c) 2010 Ioannis Gounaris, Kamarul Zaki, Pippa Corrie

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

As a member of Publisher International Linking Association, PILA, iMedPub Group’s JOP follows the Creative Commons Attribution License and Scholars Open Access publishing policies. Journal of the Pancreas is the Council Contributor Member of Council of Science Editors (CSE) and following the CSE slogan Education, Ethics, and Evidence for Editors.